The Quantellect read.As of Nov 19, 2026, 3 active firms cover FibroBiologics, Inc. Common Stock: 1 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets are tightly clustered, $6.00 to $7.00, so the covering firms are broadly aligned. The average target of $6.50 sits 683% above the current $0.83. The rating mix has held broadly steady over recent months.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Neutral
Strong Buy00%
Buy133%
Neutral267%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$6.50
+683.1% upside
Average target across 2 active firms as of Nov 19, 2026 vs $0.83 current
Highest Target$7.00
Average Target$6.50
Lowest Target$6.00
Detailed analyst forecasts for FBLG
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 1 of 3 active firms rate FBLG a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
FBLG EPS & revenue forecast
EPS · NEXT QUARTER
—
Range — – — · 0 analysts
Next period, 0 analysts expect FibroBiologics, Inc. Common Stock to earn — a share (range — – —), versus — a year earlier. Full-year consensus is $-3.00, growing to $-3.25 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 0 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering FibroBiologics, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on FBLG.
#1
MC
Matthew Caufield
HC Wainwright & Co. · Rank #155
Buy
$6.00+622.9% to target
Overall win rate
49%
+ Follow
#2
Jason Kolbert
D. Boral Capital · Rank #562
Neutral
No targeton FBLG
Overall win rate
22%
+ Follow
#3
Michael Okunewitch
Maxim Group
Neutral
No targeton FBLG
Coverage
—
+ Follow
#4
EP
Elemer Piros
Rodman & Renshaw
Buy
$12.00+1345.8% to target
Coverage
—
+ Follow
FBLG stock forecast FAQ
What is FBLG's average 12-month price target?+
The 2 active firms with a live target average $6.50 for FibroBiologics, Inc. Common Stock over the next 12 months, ranging from a $7.00 high to a $6.00 low, as of Nov 19, 2026.
Is FBLG stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 3 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for FBLG?+
The Street-high target is $7.00, and the Street-low is $6.00 (HC Wainwright & Co.). The average of all 2 active-firm targets is $6.50.
How many active Wall Street firms cover FBLG?+
3 active firms have a recognized rating on FibroBiologics, Inc. Common Stock as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering FBLG?+
Among analysts who currently cover FBLG, Matthew Caufield of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #155). Their current call is Buy with a $6.00 target.
What is FibroBiologics, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is — per share (range — – —) across 0 analysts. Full-year EPS is projected at $-3.00, rising to $-3.25 the following year.
How much revenue is FibroBiologics, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading FBLG lately?+
As of Nov 19, 2026, 1 of 3 active firms rate FBLG a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their FBLG calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.